GB2487183B - Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy - Google Patents

Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy

Info

Publication number
GB2487183B
GB2487183B GB1100042.9A GB201100042A GB2487183B GB 2487183 B GB2487183 B GB 2487183B GB 201100042 A GB201100042 A GB 201100042A GB 2487183 B GB2487183 B GB 2487183B
Authority
GB
United Kingdom
Prior art keywords
cbdv
epilepsy
treatment
phytocannabinoid
cannabidivarin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB1100042.9A
Other versions
GB2487183A8 (en
GB201100042D0 (en
GB2487183A (en
Inventor
Whalley Benjamin
Williams Claire
Stephens Gary
Futamura Takashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GW Pharma Ltd
Otsuka Pharmaceutical Co Ltd
Original Assignee
GW Pharma Ltd
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GW Pharma Ltd, Otsuka Pharmaceutical Co Ltd filed Critical GW Pharma Ltd
Priority to GB1100042.9A priority Critical patent/GB2487183B/en
Publication of GB201100042D0 publication Critical patent/GB201100042D0/en
Priority to TW100108735A priority patent/TWI583374B/en
Priority to ARP110101014 priority patent/AR080730A1/en
Priority to EA201290975A priority patent/EA036044B1/en
Priority to NZ60292511A priority patent/NZ602925A/en
Priority to EP11712658A priority patent/EP2552430A1/en
Priority to KR1020127028091A priority patent/KR101849703B1/en
Priority to EP20194696.9A priority patent/EP3763361A1/en
Priority to SG10201502480XA priority patent/SG10201502480XA/en
Priority to BR112012024480A priority patent/BR112012024480A8/en
Priority to MYPI2012004222A priority patent/MY162129A/en
Priority to SG2012070793A priority patent/SG184236A1/en
Priority to CN201180026947.4A priority patent/CN103025325B/en
Priority to AU2011234225A priority patent/AU2011234225B2/en
Priority to US13/075,873 priority patent/US9125859B2/en
Priority to JP2013501945A priority patent/JP5918748B2/en
Priority to CA2794620A priority patent/CA2794620C/en
Priority to PCT/GB2011/050649 priority patent/WO2011121351A1/en
Priority to MX2012011033A priority patent/MX2012011033A/en
Publication of GB2487183A publication Critical patent/GB2487183A/en
Priority to IL222132A priority patent/IL222132B/en
Priority to ZA2012/08141A priority patent/ZA201208141B/en
Publication of GB2487183A8 publication Critical patent/GB2487183A8/en
Priority to US14/685,753 priority patent/US10799467B2/en
Priority to AU2016244223A priority patent/AU2016244223A1/en
Priority to AU2018217303A priority patent/AU2018217303A1/en
Application granted granted Critical
Publication of GB2487183B publication Critical patent/GB2487183B/en
Priority to US17/012,448 priority patent/US20210100755A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
GB1100042.9A 2010-03-30 2011-01-04 Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy Active GB2487183B (en)

Priority Applications (25)

Application Number Priority Date Filing Date Title
GB1100042.9A GB2487183B (en) 2011-01-04 2011-01-04 Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
TW100108735A TWI583374B (en) 2010-03-30 2011-03-15 Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy
ARP110101014 AR080730A1 (en) 2010-03-30 2011-03-28 USE OF CANABIDIVARINE PHYTOCHANABINOID (CBDV) IN THE TREATMENT OF EPILEPSY
US13/075,873 US9125859B2 (en) 2010-03-30 2011-03-30 Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
CA2794620A CA2794620C (en) 2010-03-30 2011-03-30 Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy
EP11712658A EP2552430A1 (en) 2010-03-30 2011-03-30 Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy
KR1020127028091A KR101849703B1 (en) 2010-03-30 2011-03-30 Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy
EP20194696.9A EP3763361A1 (en) 2010-03-30 2011-03-30 Cannabidivarin (cbdv) for use in the treatment of epilepsy
SG10201502480XA SG10201502480XA (en) 2010-03-30 2011-03-30 Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy
BR112012024480A BR112012024480A8 (en) 2010-03-30 2011-03-30 USE OF THE PHYTOCANABINOID CANNABIDIVARIN (CBDV) IN THE TREATMENT OF EPILEPSY
MYPI2012004222A MY162129A (en) 2010-03-30 2011-03-30 Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy
SG2012070793A SG184236A1 (en) 2010-03-30 2011-03-30 Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy
CN201180026947.4A CN103025325B (en) 2010-03-30 2011-03-30 The purposes of plant cannabinoids cannabidivarin CBDV Cannabidivarol (CBDV) in treatment epilepsy
AU2011234225A AU2011234225B2 (en) 2010-03-30 2011-03-30 Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
EA201290975A EA036044B1 (en) 2010-03-30 2011-03-30 Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy
JP2013501945A JP5918748B2 (en) 2010-03-30 2011-03-30 Use of the phytocannabinoid cannabidivine (CBDV) in the treatment of epilepsy
NZ60292511A NZ602925A (en) 2010-03-30 2011-03-30 Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy
PCT/GB2011/050649 WO2011121351A1 (en) 2010-03-30 2011-03-30 Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy
MX2012011033A MX2012011033A (en) 2010-03-30 2011-03-30 Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy.
IL222132A IL222132B (en) 2010-03-30 2012-09-24 Use of cannabidivarin for the preparation of medicaments for treating epilepsy or epileptic seizures
ZA2012/08141A ZA201208141B (en) 2010-03-30 2012-10-29 Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy
US14/685,753 US10799467B2 (en) 2010-03-30 2015-04-14 Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
AU2016244223A AU2016244223A1 (en) 2010-03-30 2016-10-11 Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
AU2018217303A AU2018217303A1 (en) 2010-03-30 2018-08-17 Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
US17/012,448 US20210100755A1 (en) 2010-03-30 2020-09-04 Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1100042.9A GB2487183B (en) 2011-01-04 2011-01-04 Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy

Publications (4)

Publication Number Publication Date
GB201100042D0 GB201100042D0 (en) 2011-02-16
GB2487183A GB2487183A (en) 2012-07-18
GB2487183A8 GB2487183A8 (en) 2012-12-26
GB2487183B true GB2487183B (en) 2018-10-03

Family

ID=43639012

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1100042.9A Active GB2487183B (en) 2010-03-30 2011-01-04 Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy

Country Status (1)

Country Link
GB (1) GB2487183B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
GB202014250D0 (en) * 2020-09-10 2020-10-28 Gw Res Ltd Use of cannabidivarin in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2606334A (en) * 2021-02-12 2022-11-09 Gw Res Ltd Use of cannabidivarin in the treatment of seizures associated with canine epilepsy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2434312A (en) * 2006-01-18 2007-07-25 Gw Pharma Ltd Cannabinoid extracts for treating neurodegeneration
GB2438682A (en) * 2006-06-01 2007-12-05 Gw Pharma Ltd New use for cannabinoids
GB2479153A (en) * 2010-03-30 2011-10-05 Gw Pharma Ltd Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
WO2011121351A1 (en) * 2010-03-30 2011-10-06 Gw Pharma Limited Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2434312A (en) * 2006-01-18 2007-07-25 Gw Pharma Ltd Cannabinoid extracts for treating neurodegeneration
GB2438682A (en) * 2006-06-01 2007-12-05 Gw Pharma Ltd New use for cannabinoids
GB2479153A (en) * 2010-03-30 2011-10-05 Gw Pharma Ltd Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
WO2011121351A1 (en) * 2010-03-30 2011-10-06 Gw Pharma Limited Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy

Also Published As

Publication number Publication date
GB2487183A8 (en) 2012-12-26
GB201100042D0 (en) 2011-02-16
GB2487183A (en) 2012-07-18

Similar Documents

Publication Publication Date Title
GB2479153B (en) The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy
ZA201208141B (en) Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy
HK1254720A1 (en) Ophthalmic treatments
GB2471565B (en) Use of tetrahydrocannabivarin (THCV) in the treatment of epilepsy
PT2709604T (en) Cannabidivarin for use in the treatment of neuropathic pain
GB2487183B (en) Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
EP2790622A4 (en) Lithotripsy eye treatment
EP2740419A4 (en) Treatment instrument
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
EP2797661A4 (en) Skin treatment device
HRP20180011T1 (en) Compounds for use in the treatment of filariasis
IL232239A0 (en) Medical use
ZA201308117B (en) Avian-based treatment
GB201111247D0 (en) Treatment
GB201109119D0 (en) Treatment
GB201102267D0 (en) Treatment
GB201102282D0 (en) Treatment
GB201102276D0 (en) Treatment
GB201102275D0 (en) Treatment
GB201102273D0 (en) Treatment
GB201102272D0 (en) Treatment
GB201102271D0 (en) Treatment
GB201102277D0 (en) Treatment
GB201102288D0 (en) Treatment
GB201102284D0 (en) Treatment

Legal Events

Date Code Title Description
732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)

Free format text: REGISTERED BETWEEN 20230323 AND 20230329